Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EDARBI

« Back to Dashboard

Summary for Tradename: EDARBI

Patents:4
Applicants:1
NDAs:1
Suppliers: see list2

Pharmacology for Tradename: EDARBI

Clinical Trials for: EDARBI

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
Status: Terminated Condition: Hypertension

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone
Status: Completed Condition: Essential Hypertension

Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
Status: Recruiting Condition: Hypertension; Obesity; Type 2 Diabetes Mellitus

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Status: Completed Condition: Grade I or II Essential Hypertension

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension
Status: Completed Condition: Hypertension

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
Status: Completed Condition: Essential Hypertension

Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
Status: Not yet recruiting Condition: Hypertension

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
Status: Completed Condition: Hypertension

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
Status: Completed Condition: Hypertension

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
Status: Completed Condition: Essential Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796Feb 25, 2011RXNo7,157,584<disabled>Y<disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796Feb 25, 2011RXNo5,583,141<disabled>YY<disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796Feb 25, 2011RXYes7,572,920<disabled>Y<disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796Feb 25, 2011RXYes7,157,584<disabled>Y<disabled>
Arbor Pharms Ireland
EDARBI
azilsartan kamedoxomil
TABLET;ORAL200796Feb 25, 2011RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc